ICE
Icetana Limited
🇦🇺 ASX
🤖 TECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-18.70%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
iCetana Ltd. engages in the commercialization of video analytics software. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-12-23. The firm provides video analytics technology designed to identify abnormal anomalous actions in real-time for large scale surveillance networks. The company is engaged in the development and sale of artificial intelligence (AI) assisted video surveillance software using technology based on machine learning to provide automatic real-time anomalous event detection. Its technology is implemented across a range of private, public and government industries at approximately 40 sites on four continents. The company has three segments: Asia Pacific (APAC), North America (NA), and Europe, Middle East & Africa (EMEA). APAC segment is engaged in selling, marketing and product development efforts in Australia and the broader Asia Pacific region. NA segment is engaged in selling and marketing efforts in the United States and Canada. EMEA segment is engaged in selling and marketing efforts in Europe, the Middle East and Africa.
📈 Performance
Price History
-91.05%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.02
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ICE
1
📊 Total Capital Earnings
$-993.142
🔃 Average investment frequency
162 weeks
💵 Average investment amount
$1,497
⏰ Last time a customer invested in ICE
293 days
ICE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
100%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in ICE also invest in...
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.71%
📊 Share price
$66.50 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Company’s primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.
🙌 Performance (5Yr p.a)
11.87%
📊 Share price
$0.14 AUD
📈 HIGH PRICE GROWTH
⛏️ MINING
Want more shares? Try these...
Inca Minerals Ltd. is a junior resource company exploring for porphyries. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2008-06-19. The company is engaged in the exploration at the Riqueza Project, located in Peru, at the greater Frewena Project and the Jean Elson project, both located in the Northern Territory, and at the MaCauley Creek Project, located in Queensland. The company is focused on gold-copper porphyry deposits, copper and zinc skarn deposits and iron ore-copper-gold (IOCG) deposits. Its projects include the Frewena Projects, Jean Elson Project, MaCauley Creek Porphyry Project, Lorna May Project, Hay River Project, Riqueza Project and Cerro Rayas Project. The MaCauley Creek Project is located 100 kilometers (km) west of Townsville in Queensland. The company consists of two granted exploration permits (EPM 27124 and EPM 27163) covering 359 square kilometers (km2) and it lies within the Townsville-Mornington Island porphyry belt. The Frewena projects have 4,736 km2 of granted tenure and exploration license applications in the East Tennant IOCG province of the Northern Territory.
🙌 Performance (5Yr p.a)
37.26%
📊 Share price
$0.01 AUD
⛏️ MINING
📈 HIGH PRICE GROWTH
IBUY.AX was created on 2022-02-14 by BetaShares. The fund's investment portfolio concentrates primarily on consumer discretionary equity. IBUY.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to a portfolio of the worlds leading online retailers.
📊 Share price
$14.34 AUD
🛍️ CONSUMER
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm uses bio-safe magnetic nanoparticles to detect cancer and other diseases. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The firm operates through Research and Development segment. The company is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to Magnetic resonance imaging (MRI). The Company’s lead program has demonstrated its technology embodied in MagSense HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Its MagSense pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
🙌 Performance (5Yr p.a)
29.52%
📊 Share price
$0.05 AUD
📈 HIGH PRICE GROWTH
🩺 HEALTH CARE